AI/ML Innovations Forms Innovation Committee; Dr. Drew Dundas Appointed Chair

AI/ML Innovations Inc. has established a new Innovation Committee at the board level to guide its regulatory strategies, intellectual-property development, and product innovation within its AI-driven health technology portfolio. Dr. Drew Dundas, a seasoned medical-device innovator and current director at AIML, will lead the committee.

Dr. Dundas brings more than 25 years of expertise in translational research and product commercialization. As CTO at Earlens Corporation, he led the development of a groundbreaking non-surgical hearing device. His extensive patent portfolio and experience in guiding health-tech firms through regulatory approvals make him a valuable leader for AIML's new initiative.

In this role, Dr. Dundas will collaborate with AIML's executive team on FDA submissions, intellectual-property policies, and AI-driven product development. His leadership aims to enhance AIML's technology impact on global healthcare.

CEO Paul Duffy emphasizes that the new committee demonstrates AIML's dedication to strong governance, enhancing value for stakeholders.